Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers

Oncology Clinical Trial

Official title:

Feasibility, Acceptability, and Effect of a Symptom Management mHealth Application With Personalised Support for Children at the Early Stage of Cancer Survivorship and Their Caregivers: Pre-post Pilot Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06015009
• Other study ID #: 2022.461
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 4, 2023
• Est. completion date: July 30, 2024

Study information

• Verified date: April 2024
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot trial aims to determine the feasibility, usability, acceptability, and preliminary effect of the symptom management mHealth app. Participants meeting the aforementioned criteria (section d(i)) will be eligible to participate.

Description:

In Hong Kong, the incidence of paediatric cancer has been increasing in the past few years, from 180 new cancer cases in 2017 to 196 cases in 2019. The average 5-year survival rate for paediatric cancer patients is approximately 85% due to recent advances in cancer treatments. The success of these treatments has resulted in a rapid growth in the population of paediatric cancer survivors globally. This population now has an average lifespan of 72 years. Despite the improved survival rate, the high toxicity and low specificity of cancer treatment given at an early age induce a myriad of deleterious late effects that have a detrimental impact on survivors' physical and psychosocial well-being. Therefore, children who have completed cancer treatment require ongoing monitoring for cancer progression and survivorship care as early as possible to manage the symptoms induced by the invasive treatment. Symptom management in paediatric oncology nursing is becoming increasingly important due to the complex treatment modalities. The benefits of effective symptom management, particularly improvements in physical functioning and reduced psychological distress, are exponential for children being treated for cancer and their caregivers throughout the cancer trajectory. Paediatric oncology patients receive close monitoring of their somatic symptoms during their hospital stay, but there is a paucity of symptom management for children who have completed treatment and are at the early stage of survivorship. During the transition from hospital stay to home care, children and their caregivers may experience significant psychological distress due to their concerns about the child's health and uncertainties about coping with the potential symptom burden or cancer recurrence. During the first year after completing cancer treatment, many side effects related to the cancer or its treatment may persist, and other late effects may also develop. The unmet needs for symptom monitoring and management for paediatric cancer survivors, particularly those in the early stage of survivorship, warrant immediate attention from healthcare professionals. It is imperative for healthcare professionals to engage in the rigorous planning, development, and implementation of appropriate interventions to support symptom management for children in the early stage of cancer survivorship and their caregivers. These interventions should be implemented at discharge to manage patient-reported symptoms and improve the children's QoL and survival rate. Given the high utilisation of mobile technologies, integrating mobile technologies into current cancer survivorship care may be a promising and flexible approach for symptom management for children in the early stage of cancer survivorship and their caregivers. Digital health interventions have been shown to be effective at improving patient-reported outcomes in various patient populations, but there is a lack of such an intervention for paediatric cancer survivors and their caregivers to ameliorate their symptom burden in their local contexts (e.g., at home). The proposed study aims to develop a symptom management mHealth app to support children in the early stage of cancer survivorship and their caregivers and to evaluate its usability, feasibility, acceptability, and efficacy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: July 30, 2024
• Est. primary completion date: July 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 9 Years to 16 Years

Eligibility

Inclusion Criteria:

Chinese paediatric cancer survivors will be included if they

• are aged 9 to 16 years,
• are able to read Chinese and communicate in Chinese,
• have completed active cancer treatment (within the previous 2 years), as early symptom management support is crucial to reduce the symptom burden in survivors and their caregivers throughout their survivorship, and
• have a smartphone or tablet and are willing to install the mHealth app. The primary caregiver of the paediatric cancer survivors (either the mother or father)
• are able to read Chinese and communicate in Chinese, and
• have a smartphone or tablet and are willing to install the mHealth app with their children surviving cancer Exclusion Criteria: Chinese paediatric cancer survivors will be excluded if they
• have cognitive impairments or psychiatric illnesses
• are currently participating in other symptom management studies, or
• have evidence of secondary malignancy or recurrence The primary caregivers of the paediatric cancer survivors (either the mother or father) will be excluded if they have cognitive impairments or psychiatric illnesses.

Related Conditions & MeSH terms

• Neoplasms
• Oncology
• Survivorship

Intervention

Other:
• Symptom management mobile health application with personalised support
Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms. The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience.

Locations

Country	Name	City	State
Hong Kong	The Chinese University of Hong Kong	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of the intervention	Feasibility in terms of (1) the recruitment rate	Upon completion of the intervention (3 months)
Primary	Feasibility of the intervention	Feasibility in terms of (2) response rate	Upon completion of the intervention (3 months)
Primary	Feasibility of the intervention	Feasibility in terms of (3) intervention engagement time and adherence	Upon completion of the intervention (3 months)
Primary	Feasibility of the intervention	Feasibility in terms of (4) retention rate of the study	Upon completion of the intervention (3 months)
Primary	Acceptability of the intervention	Acceptability will be measured using a modified version of the Acceptability E-Scale (AES), a valid and reliable six-item 5-point Likert scale evaluating the acceptability of electronic self-report assessment for oncology population.	Upon completion of the intervention (3 months)
Primary	Acceptability of the intervention	Individual, semi-structured interviews will also be conducted to determine the acceptability of the intervention from participants' perspectives.	Upon completion of the intervention (3 months)
Secondary	Severity of child's symptoms	The Chinese version of the Patient-Reported Outcomes Measurement Information System® (PROMIS-25) Pediatric-25 Profile version 2.0 is a comprehensive measure document child reports of their symptoms and functioning over the previous seven days. It comprises 24 questions and a single item on pain intensity to evaluate six domains, including physical function, anxiety, depressive symptoms, fatigue, peer relationship, and pain interference. Each domain has Each item has a 5-point Likert scale ranging from ''never'' to ''almost always'' in most domains and from ''with no trouble'' to ''not able to do'' for the physical functioning domain. Higher scores indicate more of the measured symptom being experienced, which signifies worse functioning for anxiety, depression, fatigue, and pain interference, and better physical functioning, and peer relationships.	3 months after starting the intervention
Secondary	Caregivers' quality of life	Primary caregivers' quality of life will be assessed using the Chinese version of the World Health Organization's Quality of Life Instrument at baseline and 3 months after starting the intervention. It is a generic health status measure in assessing the overall QoL and general health (2 items), physical health (7 items), psychological health (6 items), social relationships (3 items), and environment (8 items) using a five-point Likert scale. The item scores were added to calculate the domain scores, where a higher score indicates better quality of life.	3 months after starting the intervention